现在的位置: 首页 >时讯速递, 进展交流>正文
[JAMA发表论文]:非心脏大手术的完全静脉麻醉与吸入麻醉
2026年11月22日 ⁄ 时讯速递, 进展交流 ⁄ [JAMA发表论文]:非心脏大手术的完全静脉麻醉与吸入麻醉已关闭评论

Original Investigation 

Total Intravenous vs Volatile Inhalational Anesthesia for Major Noncardiac Surgery: A Randomized Clinical Trial

Shaman Jhanji, Katie Booth, Louise Hiller, et al

JAMA Published Online: August 12, 2026

doi: 10.1001/jama.2026.11065

Key Points

Question  Among patients aged 50 years or older undergoing major elective noncardiac surgery, does maintaining general anesthesia with total intravenous anesthesia improve outcomes compared with volatile inhalational anesthesia?

Findings  In this pragmatic randomized clinical trial across 49 UK hospitals (n = 2508), days alive and at home at 30 days did not differ between total intravenous anesthesia and volatile anesthesia (22.5 days vs 22.4 days for TIVA vs inhalational anesthesia, respectively).

Meaning  Total intravenous anesthesia did not improve days alive and at home at 30 days compared with inhalational anesthesia.

Abstract

Importance  Older adults undergoing major noncardiac surgery experience substantial postoperative morbidity and health care use. The comparative effectiveness of total intravenous anesthesia (TIVA) vs volatile-based inhalational anesthesia on recovery and safety remains uncertain.

Objectives  To determine whether TIVA improves days alive and at home at 30 days compared with inhalational anesthesia and to evaluate differences in patient-centered outcomes and recovery.

Design, Setting, and Participants  Pragmatic, multicenter, open-label randomized clinical trial conducted in 49 UK National Health Service hospitals from January 2022 to April 2024 (final follow-up, October 2024) among patients aged 50 years or older scheduled for elective major noncardiac surgery.

Interventions  Participants were randomized 1:1 to receive maintenance of general anesthesia with either TIVA (propofol infusion) (n = 1254) or volatile-based inhalational agents (n = 1254). All other perioperative care was at clinician discretion.

Main Outcomes and Measures  The primary outcome was days alive and at home at 30 days. Secondary outcomes included days alive and at home at 90 days; mortality at 30 days, 90 days, and 6 months; Quality of Recovery–15 score at day 3; patient satisfaction (Bauer Patient Satisfaction Questionnaire) at day 1; delirium (4 As Test [4AT]) at day 3; unintentional awareness under anesthesia; and major postoperative complications within 30 days.

Results  Among the 2508 randomized participants, the mean age was 67 (SD, 8.9) years, and 55% were male. Characteristics were balanced across randomized groups. Days alive and at home at 30 days were similar between groups (mean, 22.5 [SD, 6.8] days vs 22.4 [SD, 6.6] days for TIVA vs inhalational anesthesia, respectively; incidence rate ratio, 1.00; 95% CI, 0.99-1.02; adjusted P = .68). There were no differences in days alive and at home at 90 days; mortality at 30 days, 90 days, or 6 months; or Quality of Recovery–15 score at day 3. Lower rates of thirst, hoarseness, and nausea and vomiting were reported in the TIVA group. Levels of delirium were similar between groups, with the majority (87.6%) having no delirium at day 3. Major complications occurred in 12.4% of patients overall, with no significant between-group differences. Two cases of certain or probable unintentional awareness under anesthesia were reported, both in the TIVA group.

Conclusions and Relevance  Among older adults undergoing major noncardiac surgery, TIVA did not improve days alive and at home at 30 days compared with inhalational anesthesia.

Trial Registration  ISRCTN.org Identifier: ISRCTN62903453

抱歉!评论已关闭.

×
腾讯微博